Literature DB >> 12547598

Liposomal delivery of antigen to human dendritic cells.

Melissa J Copland1, Margaret A Baird, Thomas Rades, Judith L McKenzie, Bernd Becker, Folkert Reck, Peter C Tyler, Nigel M Davies.   

Abstract

This study investigated whether formulation of antigen in mannosylated liposomes enhanced uptake and activation of dendritic cells (DC) and increased the ability of DC to induce primed T cell proliferation compared to formulation of antigen in unmodified liposomes or in solution. Immature human DC were generated from peripheral blood monocytes cultured with GM-CSF and IL-4. Uptake of antigen by DC and the degree of expression of the cell surface markers MHC class II, CD80, CD86 and the DC maturation marker CD83, was investigated by flow cytometry following incubation with liposomes or solution containing FITC-conjugated antigen. Exposure to liposomes containing FITC-ovalbumin resulted in enhanced expression of cell surface markers when compared to exposure to antigen in solution. Expression was highest following exposure to mannosylated liposomes. Mannosylated liposomes containing tetanus toxoid (TT) stimulated primed T cell proliferation more effectively than TT-neutral liposomes or TT-solution. This work suggests that mannosylated liposomes provide a versatile delivery vehicle for initiating enhanced immune responses to encapsulated peptide or protein vaccines.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12547598     DOI: 10.1016/s0264-410x(02)00536-4

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  31 in total

1.  Formulation and optimization of piroxicam proniosomes by 3-factor, 3-level Box-Behnken design.

Authors:  Ajay B Solanki; Jolly R Parikh; Rajesh H Parikh
Journal:  AAPS PharmSciTech       Date:  2007-10-19       Impact factor: 3.246

Review 2.  Click chemistry, a powerful tool for pharmaceutical sciences.

Authors:  Christopher D Hein; Xin-Ming Liu; Dong Wang
Journal:  Pharm Res       Date:  2008-05-29       Impact factor: 4.200

Review 3.  Applications of nanomaterials as vaccine adjuvants.

Authors:  Motao Zhu; Rongfu Wang; Guangjun Nie
Journal:  Hum Vaccin Immunother       Date:  2014-11-17       Impact factor: 3.452

Review 4.  Applications and perspectives of nanomaterials in novel vaccine development.

Authors:  Yingbin Shen; Tianyao Hao; Shiyi Ou; Churan Hu; Long Chen
Journal:  Medchemcomm       Date:  2017-10-17       Impact factor: 3.597

5.  A ceramide analogue stimulates dendritic cells to promote T cell responses upon virus infections.

Authors:  Curtis J Pritzl; Young-Jin Seo; Chuan Xia; Madhuvanthi Vijayan; Zachary D Stokes; Bumsuk Hahm
Journal:  J Immunol       Date:  2015-03-25       Impact factor: 5.422

Review 6.  Nanocarriers targeting dendritic cells for pulmonary vaccine delivery.

Authors:  Nitesh K Kunda; Satyanarayana Somavarapu; Stephen B Gordon; Gillian A Hutcheon; Imran Y Saleem
Journal:  Pharm Res       Date:  2012-10-09       Impact factor: 4.200

7.  Optimization of cell receptor-specific targeting through multivalent surface decoration of polymeric nanocarriers.

Authors:  Suzanne M D'Addio; Steven Baldassano; Lei Shi; Lila Cheung; Douglas H Adamson; Matthew Bruzek; John E Anthony; Debra L Laskin; Patrick J Sinko; Robert K Prud'homme
Journal:  J Control Release       Date:  2013-02-16       Impact factor: 9.776

8.  Negatively Charged Carbon Nanohorn Supported Cationic Liposome Nanoparticles: A Novel Delivery Vehicle for Anti-Nicotine Vaccine.

Authors:  Hong Zheng; Yun Hu; Wei Huang; Sabina de Villiers; Paul Pentel; Jianfei Zhang; Harry Dorn; Marion Ehrich; Chenming Zhang
Journal:  J Biomed Nanotechnol       Date:  2015-12       Impact factor: 4.099

9.  Surface-modified P(HEMA-co-MAA) nanogel carriers for oral vaccine delivery: design, characterization, and in vitro targeting evaluation.

Authors:  Matilde Durán-Lobato; Brenda Carrillo-Conde; Yasmine Khairandish; Nicholas A Peppas
Journal:  Biomacromolecules       Date:  2014-07-02       Impact factor: 6.988

Review 10.  Current state and challenges in developing oral vaccines.

Authors:  Julia E Vela Ramirez; Lindsey A Sharpe; Nicholas A Peppas
Journal:  Adv Drug Deliv Rev       Date:  2017-04-22       Impact factor: 15.470

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.